LONDON, ON, – Older patients taking a common cholesterol medication should be cautious of the impact on their kidney health. In a new study by Dr. Amit Garg, Scientist at the Lawson Health Research Institute and the Institute for Clinical Evaluative Sciences (ICES), and colleagues, one in 10 new older fibrate users experienced a 50 per cent increase in their serum creatinine.
Fibrates are a group of medications commonly used to treat high cholesterol. Recent evidence from clinical trials and case reports suggests fibrates can cause an increase to serum creatinine, an indicator of kidney health measured by a blood test, which indicates a loss of kidney health. After a number of similar experiences in their renal clinics, Dr. Garg and his colleagues felt these events merited further examination.
In a large, "real practice" study, the team examined more than 20,000 older Ontario residents with new prescriptions for fibrates. Throughout the first 90 days of their prescription, they monitored the renal outcomes in this population, and compared them to patients taking ezetimide, another cholesterol agent not known to have any renal effects.
Results show new fibrate users were more likely to experience an increase in serum creatinine; one in 10 users experienced a 50 per cent increase in the first 90 days of their prescription. As a result, these users were also more likely to consult a kidney specialist or to be hospitalized during this time.
The exact mechanism by which fibrates influence kidney function remains unclear and requires further research. This study proves that fibrates have important acute effects on kidney function and/or its measurement, to a greater extent than described in existing clinical trials data.
"At the end of the day, we want to prescribe medication with the highest benefit and the least amount of adverse events," Dr. Garg says. "When a physician decides to start a fibrate in a new patient, especially an older patient, given the information we have today they should start the patient on a dose that's appropriate, closely monitor their kidney function, and, if the kidney function goes off, either lower the dose or discontinue the drug."
The full study is published in the Annals of Internal Medicine, available here: http://www.annals.org/content/156/8/560.abstract.
Dr. Garg is also a Nephrologist and Director of the Kidney Clinical Research Unit at London Health Sciences Centre. He is also a Professor in the Departments of Medicine and Epidemiology and Biostatistics at Western University's Schulich School of Medicine & Dentistry.
To view the appointments and affiliations of the full study team, click here: http://www.annals.org/content/156/8/560.abstract
Lawson Health Research Institute. As the research institute of London Health Sciences Centre and St. Joseph's Health Care, London, and working in partnership with The University of Western Ontario, Lawson Health Research Institute is committed to furthering scientific knowledge to advance health care around the world. www.lawsonresearch.com
ICES is an independent, non-profit organization that uses population-based health information to produce knowledge on a broad range of health care issues. Our unbiased evidence provides measures of health system performance, a clearer understanding of the shifting health care needs of Ontarians, and a stimulus for discussion of practical solutions to optimize scarce resources. ICES knowledge is highly regarded in Canada and abroad, and is widely used by government, hospitals, planners, and practitioners to make decisions about care delivery and to develop policy.
For more information, please contact:
Sonya Gilpin
Communications & Public Relations
Lawson Health Research Institute
519-685-8500 ext. 75852
519-854-7164
sonya.gilpin@lawsonresearch.com
Deborah Creatura
Media Advisor, ICES
deborah.creatura@ices.on.ca
(o) 416-480-4780 or (c) 416-904-4547
Journal
Annals of Internal Medicine